Abstract
Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1177-1187 |
| Number of pages | 11 |
| Journal | Expert review of anticancer therapy |
| Volume | 18 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2 2018 |
Fingerprint
Keywords
- Gastric cancer
- PD-1
- PD-L1
- immuno-oncology
- immunotherapy
- microsatellite instability
- pembrolizumab
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Cite this
}
Pembrolizumab for the treatment of gastric cancer. / Kamath, Suneel D.; Kalyan, Aparna; Benson III, Al B.
In: Expert review of anticancer therapy, Vol. 18, No. 12, 02.12.2018, p. 1177-1187.Research output: Contribution to journal › Article
TY - JOUR
T1 - Pembrolizumab for the treatment of gastric cancer
AU - Kamath, Suneel D.
AU - Kalyan, Aparna
AU - Benson III, Al B
PY - 2018/12/2
Y1 - 2018/12/2
N2 - Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.
AB - Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.
KW - Gastric cancer
KW - PD-1
KW - PD-L1
KW - immuno-oncology
KW - immunotherapy
KW - microsatellite instability
KW - pembrolizumab
UR - http://www.scopus.com/inward/record.url?scp=85054390956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054390956&partnerID=8YFLogxK
U2 - 10.1080/14737140.2018.1526084
DO - 10.1080/14737140.2018.1526084
M3 - Article
VL - 18
SP - 1177
EP - 1187
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 12
ER -